Form 4: Acura Pharmaceuticals Director Exercises Stock Options and Receives New Grant

Director George K. Ross exercised 50,000 restricted stock units for common stock and received a new grant of 50,000 restricted stock units.

Summary

• Director George K. Ross exercised 50,000 restricted stock units for 50,000 shares of common stock on January 2, 2025.
• The director also received a new grant of 50,000 restricted stock units on the same date.
• The exercised restricted stock units were part of a grant from January 2, 2024, which vested quarterly.
• The new restricted stock units will vest quarterly starting March 2025, with accelerated vesting upon a change of control.
• The director has the option to exchange up to 40% of the new restricted stock units for cash, with the remainder exchanged for common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholders. There are no indications of any negative issues.

Positives

• The exercise of stock options indicates the director's confidence in the company's future.
• The new grant of restricted stock units aligns the director's interests with those of shareholders.

Future Outlook

The new restricted stock units will vest quarterly starting March 2025, with accelerated vesting upon a change of control. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2026, or earlier upon a change of control.

Industry Context

This is a standard practice for incentivizing and aligning the interests of company directors with shareholders through equity-based compensation.

Comparison to Industry Standards

• The use of restricted stock units is a common practice in the pharmaceutical industry for executive compensation.
• Vesting schedules, such as quarterly vesting, are typical for these types of grants.
• The option to exchange a portion of the units for cash is also a common feature in executive compensation packages.

Stakeholder Impact

• The exercise of stock options and the grant of new restricted stock units may have a minor dilutive effect on existing shareholders.
• The vesting schedule and potential for cash exchange may impact the company's cash flow in the future.

Key Dates

Keywords

stock options, restricted stock units, insider trading, equity compensation, corporate governance, Acura Pharmaceuticals, ACUR